An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial.

MLA

Wressnigg, Nina, et al. “An Inactivated Ross River Virus Vaccine Is Well Tolerated and Immunogenic in an Adult Population in a Randomized Phase 3 Trial.” Clinical and Vaccine Immunology : CVI, vol. 22, no. 3, Mar. 2015, pp. 267–73. EBSCOhost, https://doi.org/10.1128/CVI.00546-14.

APA

Wressnigg, N., van der Velden, M. V. W., Portsmouth, D., Draxler, W., O’Rourke, M., Richmond, P., Hall, S., McBride, W. J. H., Redfern, A., Aaskov, J., Barrett, P. N., & Aichinger, G. (2015). An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial. Clinical and Vaccine Immunology : CVI, 22(3), 267–273. https://doi.org/10.1128/CVI.00546-14

Chicago

Wressnigg, Nina, Maikel V W van der Velden, Daniel Portsmouth, Wolfgang Draxler, Maria O’Rourke, Peter Richmond, Stephen Hall, et al. 2015. “An Inactivated Ross River Virus Vaccine Is Well Tolerated and Immunogenic in an Adult Population in a Randomized Phase 3 Trial.” Clinical and Vaccine Immunology : CVI 22 (3): 267–73. doi:10.1128/CVI.00546-14.